Boston, MA – According to filings with the U.S. Securities and Exchange Commission, NeuroBo Pharmaceuticals is raising $17,030,344.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Richard Kang played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases. The company’s current pipeline consists of three therapeutic programs targeting COVID-19, pain indications and Alzheimer’s disease.

To learn more about NeuroBo Pharmaceuticals, visit http://www.neurobopharma.com/

Contact:
Richard Kang, President and Chief Executive Officer
857-702-9600
https://www.linkedin.com/in/richard-kang-202ab01a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved